Cargando…

Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)

BACKGROUND: Cholangiocytes are the target cells of cholangiopathies including primary sclerosing cholangitis (PSC). Vimentin is an intermediate filament protein that has been found in various types of mesenchymal cells. The aim of this study is to evaluate the role of vimentin in the progression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tianhao, Kyritsi, Konstantina, Wu, Nan, Francis, Heather, Yang, Zhihong, Chen, Lixian, O'Brien, April, Kennedy, Lindsey, Ceci, Ludovica, Meadows, Vik, Kusumanchi, Praveen, Wu, Chaodong, Baiocchi, Leonardo, Skill, Nicholas J., Saxena, Romil, Sybenga, Amelia, Xie, Linglin, Liangpunsakul, Suthat, Meng, Fanyin, Alpini, Gianfranco, Glaser, Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838376/
https://www.ncbi.nlm.nih.gov/pubmed/31522982
http://dx.doi.org/10.1016/j.ebiom.2019.09.013
_version_ 1783467210865377280
author Zhou, Tianhao
Kyritsi, Konstantina
Wu, Nan
Francis, Heather
Yang, Zhihong
Chen, Lixian
O'Brien, April
Kennedy, Lindsey
Ceci, Ludovica
Meadows, Vik
Kusumanchi, Praveen
Wu, Chaodong
Baiocchi, Leonardo
Skill, Nicholas J.
Saxena, Romil
Sybenga, Amelia
Xie, Linglin
Liangpunsakul, Suthat
Meng, Fanyin
Alpini, Gianfranco
Glaser, Shannon
author_facet Zhou, Tianhao
Kyritsi, Konstantina
Wu, Nan
Francis, Heather
Yang, Zhihong
Chen, Lixian
O'Brien, April
Kennedy, Lindsey
Ceci, Ludovica
Meadows, Vik
Kusumanchi, Praveen
Wu, Chaodong
Baiocchi, Leonardo
Skill, Nicholas J.
Saxena, Romil
Sybenga, Amelia
Xie, Linglin
Liangpunsakul, Suthat
Meng, Fanyin
Alpini, Gianfranco
Glaser, Shannon
author_sort Zhou, Tianhao
collection PubMed
description BACKGROUND: Cholangiocytes are the target cells of cholangiopathies including primary sclerosing cholangitis (PSC). Vimentin is an intermediate filament protein that has been found in various types of mesenchymal cells. The aim of this study is to evaluate the role of vimentin in the progression of biliary damage/liver fibrosis and whether there is a mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) model of PSC. METHODS: In vivo studies were performed in 12 wk. Mdr2(−/−) male mice with or without vimentin Vivo-Morpholino treatment and their corresponding control groups. Liver specimens from human PSC patients, human intrahepatic biliary epithelial cells (HIBEpiC) and human hepatic stellate cell lines (HHSteCs) were used to measure changes in epithelial-to-mesenchymal transition (EMT). FINDINGS: There was increased mesenchymal phenotype of cholangiocytes in Mdr2(−/−) mice, which was reduced by treatment of vimentin Vivo-Morpholino. Concomitant with reduced vimentin expression, there was decreased liver damage, ductular reaction, biliary senescence, liver fibrosis and TGF-β1 secretion in Mdr2(−/−) mice treated with vimentin Vivo-Morpholino. Human PSC patients and derived cell lines had increased expression of vimentin and other mesenchymal markers compared to healthy controls and HIBEpiC, respectively. In vitro silencing of vimentin in HIBEpiC suppressed TGF-β1-induced EMT and fibrotic reaction. HHSteCs had decreased fibrotic reaction and increased cellular senescence after stimulation with cholangiocyte supernatant with reduced vimentin levels. INTERPRETATION: Our study demonstrated that knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes, which leads to decreased biliary senescence and liver fibrosis. Inhibition of vimentin may be a key therapeutic target in the treatment of cholangiopathies including PSC. FUND: National Institutes of Health (NIH) awards, VA Merit awards.
format Online
Article
Text
id pubmed-6838376
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68383762019-11-12 Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC) Zhou, Tianhao Kyritsi, Konstantina Wu, Nan Francis, Heather Yang, Zhihong Chen, Lixian O'Brien, April Kennedy, Lindsey Ceci, Ludovica Meadows, Vik Kusumanchi, Praveen Wu, Chaodong Baiocchi, Leonardo Skill, Nicholas J. Saxena, Romil Sybenga, Amelia Xie, Linglin Liangpunsakul, Suthat Meng, Fanyin Alpini, Gianfranco Glaser, Shannon EBioMedicine Research paper BACKGROUND: Cholangiocytes are the target cells of cholangiopathies including primary sclerosing cholangitis (PSC). Vimentin is an intermediate filament protein that has been found in various types of mesenchymal cells. The aim of this study is to evaluate the role of vimentin in the progression of biliary damage/liver fibrosis and whether there is a mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) model of PSC. METHODS: In vivo studies were performed in 12 wk. Mdr2(−/−) male mice with or without vimentin Vivo-Morpholino treatment and their corresponding control groups. Liver specimens from human PSC patients, human intrahepatic biliary epithelial cells (HIBEpiC) and human hepatic stellate cell lines (HHSteCs) were used to measure changes in epithelial-to-mesenchymal transition (EMT). FINDINGS: There was increased mesenchymal phenotype of cholangiocytes in Mdr2(−/−) mice, which was reduced by treatment of vimentin Vivo-Morpholino. Concomitant with reduced vimentin expression, there was decreased liver damage, ductular reaction, biliary senescence, liver fibrosis and TGF-β1 secretion in Mdr2(−/−) mice treated with vimentin Vivo-Morpholino. Human PSC patients and derived cell lines had increased expression of vimentin and other mesenchymal markers compared to healthy controls and HIBEpiC, respectively. In vitro silencing of vimentin in HIBEpiC suppressed TGF-β1-induced EMT and fibrotic reaction. HHSteCs had decreased fibrotic reaction and increased cellular senescence after stimulation with cholangiocyte supernatant with reduced vimentin levels. INTERPRETATION: Our study demonstrated that knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes, which leads to decreased biliary senescence and liver fibrosis. Inhibition of vimentin may be a key therapeutic target in the treatment of cholangiopathies including PSC. FUND: National Institutes of Health (NIH) awards, VA Merit awards. Elsevier 2019-09-12 /pmc/articles/PMC6838376/ /pubmed/31522982 http://dx.doi.org/10.1016/j.ebiom.2019.09.013 Text en Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research paper
Zhou, Tianhao
Kyritsi, Konstantina
Wu, Nan
Francis, Heather
Yang, Zhihong
Chen, Lixian
O'Brien, April
Kennedy, Lindsey
Ceci, Ludovica
Meadows, Vik
Kusumanchi, Praveen
Wu, Chaodong
Baiocchi, Leonardo
Skill, Nicholas J.
Saxena, Romil
Sybenga, Amelia
Xie, Linglin
Liangpunsakul, Suthat
Meng, Fanyin
Alpini, Gianfranco
Glaser, Shannon
Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
title Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
title_full Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
title_fullStr Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
title_full_unstemmed Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
title_short Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
title_sort knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the mdr2(−/−) mouse model of primary sclerosing cholangitis (psc)
topic Research paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838376/
https://www.ncbi.nlm.nih.gov/pubmed/31522982
http://dx.doi.org/10.1016/j.ebiom.2019.09.013
work_keys_str_mv AT zhoutianhao knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT kyritsikonstantina knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT wunan knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT francisheather knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT yangzhihong knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT chenlixian knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT obrienapril knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT kennedylindsey knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT ceciludovica knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT meadowsvik knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT kusumanchipraveen knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT wuchaodong knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT baiocchileonardo knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT skillnicholasj knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT saxenaromil knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT sybengaamelia knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT xielinglin knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT liangpunsakulsuthat knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT mengfanyin knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT alpinigianfranco knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc
AT glasershannon knockdownofvimentinreducesmesenchymalphenotypeofcholangiocytesinthemdr2mousemodelofprimarysclerosingcholangitispsc